As shown in Fig. 5e, PD-L1 surface expression was reduced in ARAC-treated tumors in both hematopoietic (CD45+ , primarily immune cells) and nonhematopoietic (CD45−, primarily cancer cells) cell populations, confirming the efficacy of PD-L1 antibody on the nanoconstruct. This evidence concerns the gene PTPRC and cancer.